Management

Erik Digman Wiklund
Erik Digman Wiklund
Chief Executive Officer
Close
Erik Digman Wiklund
Erik Digman Wiklund
Chief Executive Officer

Former consultant in the Pharma & Healthcare practice of McKinsey & Company, combined with a PhD in cancer research.

Erik Digman Wiklund was hired as the Company’s CFO in April 2017, and transitioned into the CBO role in October 2018. In October 2021 he was appinted CEO of Targovax. Dr. Wiklund previously worked for the Norwegian cancer biotechnology company Algeta ASA and the nutraceutical company Aker Biomarine Antarctic AS. He also has management consulting experience from the Pharma & Health Care practice of McKinsey & Company. Dr. Wiklund holds a PhD in Molecular Biology from Aarhus University, Denmark, and the Garvan Institute of Medical Research in Sydney, Australia. Dr. Wiklund is a Swedish and Norwegian citizen, residing in Norway.

Shares
Share options 750,000

 

Dr Lone Ottesen
Dr Lone Ottesen
Chief Development Officer
Close
Dr Lone Ottesen
Dr Lone Ottesen
Chief Development Officer

Dr Ottesen is a highly experienced drug developer with extensive experience across the global oncology and immune-oncology drug development spectrum with nearly 20 years in the pharmaceutical industry in both early- and late-phase development. Lone got her MD and PhD at Aarhus University in Denmark and has held roles of increasing seniority in GSK, Eisai and latest AstraZeneca where she was the Global Clinical Head for two assets in pivotal clinical development as well as leading the development of durvalumab in breast and gynecological cancers. Lone will be spearheading the clinical development program for the Targovax portfolio including the planned registration-directed trial in anti-PD1 refractory melanoma for the lead asset ONCOS-102.

Magnus Jäderberg
Magnus Jäderberg
Chief Medical Officer
Close
Magnus Jäderberg
Magnus Jäderberg
Chief Medical Officer

A pharmaceutical physician with more than 30 years in various R&D functions and general management.

Magnus Jäderberg is a pharmaceutical physician with experience from more than 30 years in various R&D functions including clinical research, medical affairs, pharmacovigilance, strategic product development and general management. He is experienced in all phases of clinical research, including clinical pharmacology, dose finding, registration, post-launch product differentiation and pharmacovigilance. Dr. Jäderberg’s worked on the late stage development, registration and launch of Rapamune (sirolimus) and Yervoy (ipilimumab). Prior to joining Targovax, he held roles at national, European and global level at GSK, Pharmacia, Wyeth and most recently as Chief Medical Officer of Bristol Myers Squibb (Europe). Dr. Jaderberg qualified in medicine at Karolinska Institute, Stockholm, Sweden, and is a fellow of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom. He is a Swedish citizen and resides in the United Kingdom.

Shares 20,000
Share options 1080,000

 

Victor Levitsky
Victor Levitsky
Chief Scientific Officer
Close
Victor Levitsky
Victor Levitsky
Chief Scientific Officer

Dr Levitsky is a seasoned internationally recognized expert in immunology, oncology, T-cell immunotherapy and immuno-oncology with in-depth knowledge of preclinical, translational and early stage clinical drug development. He brings extensive experience in pre-clinical drug development of protein-based biologics and small molecules. Dr Levitsky is a medical doctor with a PhD in Virology and post-doctoral training in tumor biology at Karolinska Institute, Sweden. He spent the first 20 years of his career as an academic research scientist, including Associate Professor positions at the Karolinska Institute in Sweden and the Johns Hopkins University School of Medicine in the USA. Before joining Targovax Dr Levitsky served as Tumor Immunology Leader and Senior Principal Scientist with Roche in Zurich, and his most recent position has been VP, Head of Oncology Research at Molecular Partners, Zurich, Switzerland. Dr Levitsky is a Swedish and Russian citizen and resides in Switzerland.

Shares 10,000
Share options 500,000
Ola Melin
Ola Melin
Head of Manufacturing
Close
Ola Melin
Ola Melin
Head of Manufacturing

With over 25 years’ experience in Biologics development, manufacturing and supply 

Ola Melin joins Targovax with over 25 years’ experience in Biologics development, manufacturing, and supply, most recently as Director of Technical Operations at OxThera AB, where he was responsible for clinical supply and for establishing a commercially ready manufacturing process and supply chain. Prior to that Ola spent eighteen years at Biovitrum and Sobi AB, where he held senior leadership roles as Head of External Manufacturing and Head of Product Supply, as well as other CMC positions. Ola started his career with manufacturing process development at Pharmacia. Ola has studied Biochemical engineering at Mälardalen University.

Shares
Share options 250,000
Ingunn Munch Lindvig
Ingunn Munch Lindvig
VP, Regulatory Affairs
Close
Ingunn Munch Lindvig
Ingunn Munch Lindvig
VP, Regulatory Affairs

Extensive experience with regulatory strategy and more than 20 years in the pharma and biotech industry

Ingunn Munch Lindvig has more than 20 years in the pharma and biotech industry. She has extensive experience with regulatory strategy and delivery on regulatory plans across a range of pharmaceutical products. Prior to joining Targovax Dr Lindvig was Head of Regulatory Affairs at Nordic Nanovector ASA for five years and she also led the regulatory function at Photocure ASA for seven years. Dr Lindvig was part of the Regulatory team at Nycomed Imaging/Nycomed Amersham/GE Healthcare.

Dr Lindvig holds a PhD in physiology from University of Oslo, Norway.  She is a Norwegian citizen and resides in Norway.

Shares 10,000
Share options 267,000
Øystein Soug
Øystein Soug
Special Advisor and Interim Chief Financial Officer
Close
Øystein Soug
Øystein Soug
Special Advisor and Interim Chief Financial Officer

20 years in international banking and industry; previous CFO of Algeta ASA.

Øystein Soug has experience from 20 years in international banking industry and biotech. The last six years before joining the Company he was CFO of Algeta ASA, which developed and launched Xofigo and was sold for USD 2.9 billion to Bayer. Before his current CEO role, he was CFO of Targovax from May 2015 to October 2016. Prior to biotech, Mr. Soug held several CFO and business development positions with the Orkla Group and the European Bank for Reconstruction and Development (EBRD) in Norway and Russia. Oystein is an economist by training from the University of St. Gallen (lic.oec.HSG). Mr. Soug is a Norwegian citizen and resides in Norway.

Shares 200,000
Share options 1,310,000